{"schema_version":"secwatch.filing_event.v1","accession":"0000313616-25-000180","form_type":"8-K","ticker":"DHR","cik":"0000313616","company_name":"DANAHER CORP /DE/","filed_at":"2025-10-21T23:59:59+00:00","discovered_at":"2026-05-14T18:02:41.684514+00:00","generated_at":"2026-05-17T03:07:22.482112+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Danaher Q3 2025: EPS $1.27 GAAP, $1.89 adjusted; revenue up 4.5% to $6.1B","bullets":["Net earnings $908M ($1.27 diluted EPS); non-GAAP adjusted diluted EPS $1.89.","Revenue $6.1B, up 4.5% YoY; non-GAAP core revenue up 3.0% YoY.","Operating cash flow $1.7B; non-GAAP free cash flow $1.4B.","Full-year 2025 adjusted diluted EPS guidance maintained at $7.70-$7.80; core revenue expected low-single-digit growth.","Cepheid respiratory revenue better-than-anticipated; bioprocessing momentum cited as key driver."],"urls":{"canonical":"https://secwatch.observer/filing/0000313616-25-000180","json":"https://secwatch.observer/filing/0000313616-25-000180.json","markdown":"https://secwatch.observer/filing/0000313616-25-000180.md","text":"https://secwatch.observer/filing/0000313616-25-000180.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/313616/000031361625000180/0000313616-25-000180-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/313616/000031361625000180/dhr-20251021.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T03:07:22.482112+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}